VistaGen Therapeutics, Inc.
VTGN
Rank in Stocks
#29307
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Share Price
$0.1844
Last synced: 2026-11-09
Market Cap
$8.18M
Change (1 day)
12.58%
Change (1 year)
-95.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade VistaGen Therapeutics, Inc. (VTGN)
Category
Healthcare
EPS for VistaGen Therapeutics, Inc. (VTGN)
EPS as of June 2026 TTM: $-1.70
According to VistaGen Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.70. At the end of 2025 the company had an EPS of $-1.67, a decrease compared to its 2024 EPS of $-1.52.
EPS history for VistaGen Therapeutics, Inc. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.70 | 1.80% |
| 2025 | $-1.67 | 9.87% |
| 2024 | $-1.52 | -82.14% |
| 2023 | $-8.51 | 15.31% |
| 2022 | $-7.38 | -49.93% |
| 2021 | $-14.74 | 3.73% |
| 2020 | $-14.21 | -44.99% |
| 2019 | $-25.83 | -16.62% |
| 2018 | $-30.98 | -24.16% |
| 2017 | $-40.85 | -94.90% |
| 2016 | $-801.28 | 151.76% |
| 2015 | $-318.27 | 292.93% |
| 2014 | $-81.00 | -81.03% |
| 2013 | $-426.99 | -14.11% |
| 2012 | $-497.11 | 107,967.39% |
| 2011 | $-0.46 | 0.00% |
| 2010 | $-0.46 | -59.29% |
| 2009 | $-1.13 | 18.95% |
| 2008 | $-0.95 | 239.29% |
| 2007 | $-0.28 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,021.18% |
US
|
|
| $-7.07 | 315.88% |
US
|
|
| $-5.29 | 211.18% |
AU
|
|
| $12.88 | -857.65% |
BE
|
|
| $21.56 | -1,368.24% |
NL
|
Questions about VistaGen Therapeutics, Inc.'s earnings per share (EPS)
What is VistaGen Therapeutics, Inc.'s earnings per share (EPS)?
VistaGen Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.70, as of Jun 2026.
What was VistaGen Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, VistaGen Therapeutics, Inc.'s earnings per share (EPS) was $-1.67, compared with $-1.52 in 2024.
How has VistaGen Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, VistaGen Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.52) and lowest in 2021 ($-14.74).
How does VistaGen Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
VistaGen Therapeutics, Inc.'s earnings per share (EPS) ($-1.70) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.